title: In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas.
abstract: Treatment for glioblastoma consists of radiotherapy and temozolomide-based chemotherapy. However, virtually all patients recur, leading to a fatal outcome. Receptor tyrosine kinase (RTK)-targeted therapy has been the focus of attention in novel treatment options for these patients. Here, we compared the efficacy of imatinib, sunitinib, and cediranib in glioblastoma models. In the present work, the biologic effect of the drugs was screened by viability, cell cycle, apoptosis, migration, and invasion in vitro assays or in vivo by chick chorioallantoic membrane assay. Intracellular signaling was assessed by Western blot and the RTK targets were identified using phospho-RTK arrays. The amplified status of KIT, PDGFRA, and VEGFR2 genes was assessed by quantitative polymerase chain reaction. In a panel of 10 glioblastoma cell lines, we showed that cediranib was the most potent. In addition, cediranib and sunitinib synergistically sensitize the cells to temozolomide. Cediranib efficacy was shown to associate with higher cytostatic and unique cytotoxic effects in vitro and both antitumoral and antiangiogenic activity in vivo, which could associate with its great capacity to inhibit mitogen-activated protein kinase (MAPK) and AKT pathways. The molecular status of KIT, PDGFRA, and VEGFR2 did not predict glioblastoma cell responsiveness to any of the RTK inhibitors. Importantly, phospho-RTK arrays revealed novel targets for cediranib and sunitinib therapy. In conclusion, the novel targets found may be of value as future biomarkers for therapy response in glioblastoma and lead to the rational selection of patients for effective molecular targeted treatment.
authors.affiliation: Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, Braga, Portugal ; ICVS/3B's, PT Government Associate Laboratory, Braga, Guimarães, Portugal ; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
authors.forename: Olga
authors.initials: O
authors.lastname: Martinho
authors.forename: Renato
authors.initials: R
authors.lastname: Silva-Oliveira
authors.forename: Vera
authors.initials: V
authors.lastname: Miranda-Gonçalves
authors.forename: Carlos
authors.initials: C
authors.lastname: Clara
authors.forename: José Reynaldo
authors.initials: JR
authors.lastname: Almeida
authors.forename: André Lopes
authors.initials: AL
authors.lastname: Carvalho
authors.forename: João Taborda
authors.initials: JT
authors.lastname: Barata
authors.forename: Rui Manuel
authors.initials: RM
authors.lastname: Reis
references.citation: Science. 2007 Oct 12;318(5848):287-90
references.pmid: 17872411
references.citation: J Clin Oncol. 2010 Jun 10;28(17):2817-23
references.pmid: 20458050
references.citation: Radiother Oncol. 2011 Jan;98(1):1-14
references.pmid: 21159396
references.citation: J Neurooncol. 2010 Feb;96(3):349-57
references.pmid: 19629393
references.citation: Nat Rev Cancer. 2010 May;10(5):319-31
references.pmid: 20414201
references.citation: Invest New Drugs. 2010 Oct;28(5):554-60
references.pmid: 19603143
references.citation: J Pathol. 2011 Apr;223(5):626-34
references.pmid: 21341272
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1540-9
references.pmid: 18316579
references.citation: Basic Clin Pharmacol Toxicol. 2009 Mar;104(3):241-52
references.pmid: 19159435
references.citation: Lancet Neurol. 2008 Dec;7(12):1152-60
references.pmid: 19007739
references.citation: Oncogene. 2007 Jun 7;26(27):3909-19
references.pmid: 17325667
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: Cancer Cell. 2011 Dec 13;20(6):810-7
references.pmid: 22137795
references.citation: Br J Cancer. 2009 Sep 15;101(6):973-82
references.pmid: 19707201
references.citation: Anticancer Res. 2010 Dec;30(12):4987-92
references.pmid: 21187479
references.citation: J Neurooncol. 2011 Jul;103(3):491-501
references.pmid: 20872043
references.citation: Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3749-54
references.pmid: 21321221
references.citation: Neuro Oncol. 2010 Aug;12(8):822-33
references.pmid: 20179017
references.citation: Crit Rev Oncol Hematol. 2006 Sep;59(3):181-93
references.pmid: 16860996
references.citation: J Cancer Res Clin Oncol. 2006 Sep;132(9):589-99
references.pmid: 16736141
references.citation: Cancer Biol Ther. 2003 Jul-Aug;2(4):330-42
references.pmid: 14508101
references.citation: J Clin Oncol. 2009 May 20;27(15):2542-52
references.pmid: 19332720
references.citation: J Natl Cancer Inst. 2007 Nov 7;99(21):1583-93
references.pmid: 17971532
references.citation: J Natl Compr Canc Netw. 2011 Apr;9(4):403-7
references.pmid: 21464145
references.citation: Cancer Cell. 2007 Jan;11(1):83-95
references.pmid: 17222792
references.citation: Cancer Res. 2003 Jul 15;63(14):4009-16
references.pmid: 12873999
references.citation: Eur J Cancer. 2009 Sep;45(13):2352-9
references.pmid: 19505817
references.citation: PLoS One. 2012;7(1):e30769
references.pmid: 22292035
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Mol Cancer Ther. 2011 May;10(5):861-73
references.pmid: 21441409
references.citation: Cancer Res. 2011 Jan 1;71(1):19-28
references.pmid: 21199795
references.citation: Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3041-6
references.pmid: 22323597
references.citation: Cancer Res. 2012 Apr 1;72(7):1614-20
references.pmid: 22311673
references.citation: Lancet Oncol. 2009 May;10(5):459-66
references.pmid: 19269895
references.citation: Gynecol Oncol. 2008 Nov;111(2):350-5
references.pmid: 18708242
references.citation: Int J Cancer. 2009 Mar 1;124(5):1060-71
references.pmid: 19048625
references.citation: J Clin Oncol. 2009 Feb 10;27(5):740-5
references.pmid: 19114704
references.citation: N Engl J Med. 2007 Jan 11;356(2):115-24
references.pmid: 17215529
references.citation: Neuro Oncol. 2007 Oct;9(4):412-23
references.pmid: 17622648
references.citation: BioDrugs. 2009;23(6):377-89
references.pmid: 19894779
references.citation: J Neurooncol. 2011 Nov;105(2):181-90
references.pmid: 21516367
references.citation: N Engl J Med. 2001 Apr 5;344(14):1038-42
references.pmid: 11287973
references.citation: Oncogene. 2006 Aug 10;25(35):4913-22
references.pmid: 16547494
references.citation: Clin Cancer Res. 2006 Aug 15;12(16):4899-907
references.pmid: 16914578
references.citation: N Engl J Med. 2008 Jul 31;359(5):492-507
references.pmid: 18669428
references.citation: Clin Cancer Res. 2003 Jan;9(1):327-37
references.pmid: 12538485
references.citation: Hum Mol Genet. 2013 Jan 1;22(1):84-95
references.pmid: 23035050
references.citation: Tissue Eng Part A. 2012 Jun;18(11-12):1203-12
references.pmid: 22439824
references.citation: Cancer Res. 2005 May 15;65(10):4389-400
references.pmid: 15899831
references.citation: Nature. 2008 Oct 23;455(7216):1061-8
references.pmid: 18772890
references.citation: Neuro Oncol. 2010 Mar;12(3):304-16
references.pmid: 20167819
references.citation: Science. 2007 May 18;316(5827):1039-43
references.pmid: 17463250
references.citation: Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):483-91
references.pmid: 21095630
references.citation: Cell Oncol. 2007;29(5):399-408
references.pmid: 17726262
references.citation: N Engl J Med. 2002 Aug 15;347(7):472-80
references.pmid: 12181401